{
  "docId": "019de075-4481-714f-9573-a4ad96e0f148",
  "docSlug": "816ee2fbc8fb2bf52edc4f2891aaa98f",
  "documentTitle": "Dare Bioscience | Investor Presentation Deck | 27 slides",
  "authorId": "dare-bioscience",
  "authorName": "Daré Bioscience",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-07-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.2938006,
  "pageNumber": 22,
  "pageCount": 27,
  "prevPage": 21,
  "nextPage": 23,
  "slideType": "traction",
  "function": "show_traction",
  "density": "dense",
  "nDataPoints": 0,
  "notes": "Includes yellow highlighting on key phrases.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de075-4481-714f-9573-a4ad96e0f148/22",
  "deckHref": "/decks/019de075-4481-714f-9573-a4ad96e0f148",
  "deckJsonHref": "/decks/019de075-4481-714f-9573-a4ad96e0f148.json",
  "deckAnchorHref": "/decks/019de075-4481-714f-9573-a4ad96e0f148#slide-22",
  "components": [
    {
      "bbox": {
        "h": 0.15,
        "w": 0.78,
        "x": 0.11,
        "y": 0.46
      },
      "kind": "list",
      "text": "Sildenafil Cream-treated patients also showed improvements in the secondary endpoint and pre-specified exploratory endpoints that evaluated various aspects of the sexual experience: Sexual satisfaction, Arousal lubrication, Achievement and pleasure of orgasm, Sexual desire",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "8e980733-42d7-451c-b314-24627a986311",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.78,
        "x": 0.11,
        "y": 0.37
      },
      "kind": "list",
      "text": "Sildenafil Cream-treated patients showed meaningful improvement in the co-primary endpoint assessment that evaluated change from baseline in the Arousal-Sensation Domain of the Sexual Function Questionnaire, although the endpoint did not achieve statistical significance.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "f8ad7f24-9fad-40cc-aea6-38c2cbf8c6f5",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.78,
        "x": 0.11,
        "y": 0.28
      },
      "kind": "paragraph",
      "text": "Positive findings from the exploratory Phase 2b RESPOND study of Sildenafil Cream, 3.6% in women with Female Sexual Arousal Disorder support continued development of Sildenafil Cream and selection of proposed primary endpoint assessments for a Phase 3 study",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "a80707f5-7ac1-4593-8c3e-4896ad672c9d",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.04,
        "w": 0.78,
        "x": 0.11,
        "y": 0.19
      },
      "kind": "title",
      "text": "Sildenafil Cream, 3.6% - Phase 2b RESPOND Study – Highlights",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "00d7712d-c453-49cd-a4ff-d61776fc0a86",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}